Showing results (41-50 of 68) with videos related to
Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|September 23, 2011
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionCindy L O'Bryant, Paul Haluska, Lee Rosen, et al.Clinical Lung Cancer|July 26, 2022
A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181John Michael Varlotto, Zhuoxin Sun, Bonnie Ky, et al.Chest|November 17, 2021
Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy ProgramsYusef A Syed, William Stokes, Manali Rupji, et al.Cancer|February 2, 2012
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results dataChristopher L Ellington, Michael Goodman, Scott A Kono, et al.Cancer Chemotherapy and Pharmacology|May 13, 2010
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II doseKyle D Holen, Chandra P Belani, George Wilding, et al.Journal of Clinical Pharmacology|January 15, 2011
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.International Journal of Nanomedicine|November 1, 2012
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.Journal of Liposome Research|July 15, 2010
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumorsWilliam C Zamboni, Lauren J Maruca, Sandra Strychor, et al.The Oncologist|February 17, 2021
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 StudyJohn M Varlotto, Zhuoxin Sun, Bonnie Ky, et al.JAMA Network Open|October 13, 2025
Survival Determinants and Sociodemographic Disparities in Early-Onset Non-Small Cell Lung CancerIrem Kar, Farheen Vhora, Maroun Bou Zerdan, et al.Pageof 7